Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M. Krege S, et al. Among authors: rexer h. BJU Int. 2014 Mar;113(3):429-36. doi: 10.1111/bju.12437. BJU Int. 2014. PMID: 24053564 Clinical Trial.
The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma.
Doehn C, Grünwald V, Steiner T, Follmann M, Rexer H, Krege S. Doehn C, et al. Among authors: rexer h. Dtsch Arztebl Int. 2016 Sep 5;113(35-36):590-6. doi: 10.3238/arztebl.2016.0590. Dtsch Arztebl Int. 2016. PMID: 27658472 Free PMC article. Review.
[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO].
Rexer H, Retz M, Albers P. Rexer H, et al. Urologe A. 2016 Nov;55(11):1491-1493. doi: 10.1007/s00120-016-0248-5. Urologe A. 2016. PMID: 27714413 Clinical Trial. German. No abstract available.
[First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)].
Rexer H, Ohlmann CH, Retz M. Rexer H, et al. Urologe A. 2017 May;56(5):659-661. doi: 10.1007/s00120-017-0380-x. Urologe A. 2017. PMID: 28349185 Clinical Trial. German. No abstract available.
112 results